Ebb TIDES As Takeda’s Dengue Contender Weaker At 18 Months
Lower DENV-3 Efficacy A Concern?
Executive SummaryTakeda's TAK-003 generally positive in new 18-month analysis, but efficacy falls versus 12 months and lowest effectiveness again seen against serotype 3.
You may also be interested in...
Promising data from Phase I clinical trials of a dengue vaccine and a $24.3m award by UN agencies for its Easyfive-TT pentavalent vaccine bode well for Panacea Biotec, but are they enough to turn the company’s fortunes around?
Japanese firm in discussions with regulator as high-need novel therapy for spinocerebellar degeneration misses endpoint but shows promise in pooled analysis.
Full, planned acquisition of Tokyo-based operation will give US biotech giant a firmer foothold in key market and new platform for Otezla growth.